Burapitant
Overview[edit]
Burapitant is a chemical compound that acts as a neurokinin-1 receptor antagonist. It is primarily researched for its potential use in treating conditions such as nausea and vomiting, particularly those induced by chemotherapy.
Chemical Structure[edit]
Burapitant is characterized by its unique chemical structure, which allows it to effectively bind to and inhibit the neurokinin-1 receptor. This receptor is involved in the body's response to stress and pain, making Burapitant a compound of interest in the development of new therapeutic agents.
Mechanism of Action[edit]
Burapitant works by blocking the action of substance P, a neuropeptide that binds to the neurokinin-1 receptor. By inhibiting this interaction, Burapitant can reduce the symptoms associated with emesis and potentially other conditions mediated by substance P.
Potential Applications[edit]
The primary application of Burapitant is in the management of chemotherapy-induced nausea and vomiting (CINV). It may also have potential uses in treating other conditions where substance P is implicated, such as certain types of pain and depression.
Research and Development[edit]
Research into Burapitant is ongoing, with studies focusing on its efficacy, safety, and potential side effects. As a neurokinin-1 receptor antagonist, it is part of a class of drugs that are being explored for their ability to improve the quality of life for patients undergoing cancer treatment.
Related pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
